The Potential of Gallic Acid as a Radiosensitizer on Human Prostate Cancer: A Systematic Review of Preclinical Studies
- Author:
Agung Tri Cahyono
1
;
Melva Louisa
2
;
Tiara Bunga Mayang Permata
1
;
Handoko
1
;
Endang Nuryadi
1
;
Henry Kodrat
1
;
Heri Wibowo
3
;
Agus Rizal Ardy Hariandy Hamid
4
;
Sri Mutya Sekarutami
1
;
Soehartati Argadikoesoema Gondhowiardjo
1
Author Information
- Publication Type:Review
- Keywords: Gallic acid, Radiotherapy, Radiobiology, Apoptosis, Prostate cancer
- From:Malaysian Journal of Medicine and Health Sciences 2021;17(No.2):246-254
- CountryMalaysia
- Language:English
- Abstract: Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.
- Full text:11.2021my1045.pdf
